OR WAIT null SECS
September 19, 2022
Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.
Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.
September 16, 2022
EMA has recommended approval of Enjaymo for the treatment of hemolytic anemia in adult patients with cold agglutinin disease.
September 14, 2022
MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.
WHO has awarded prequalification to GSK’s Mosquirix, an approved malaria vaccine.
Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.
September 09, 2022
Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.
Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.
September 08, 2022
In partnership with the University of Pittsburgh, ElevateBio will open its next manufacturing center in the city.
Roche’s acquisition of Good Therapeutics grants them rights to the company's conditionally activated PD-1-regulated IL-2 program.